|
1.
|
|
6 p, 916.0 KB |
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
/
De Mattos-Arruda, Leticia (Universitat Autònoma de Barcelona) ;
Mayor, Regina (Vall d'Hebron Institut d'Oncologia) ;
Ng, Charlotte K. Y. (Memorial Sloan Kettering Cancer Center) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ;
Torrejon, Davis (Vall d'Hebron Institut d'Oncologia) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Raventós, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Tang, Jiabin (Memorial Sloan Kettering Cancer Center) ;
Guerini-Rocco, Elena (Memorial Sloan Kettering Cancer Center) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lois, Sergio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Marín, Oscar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de la Cruz, Xavier (Institució Catalana de Recerca i Estudis Avançats) ;
Piscuoglio, Salvatore (Memorial Sloan Kettering Cancer Center) ;
Towers, Russel (Department of Surgery, Memorial Sloan Kettering Cancer Center) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona) ;
Carles, Joan (Vall d'Hebron Institut d'Oncologia) ;
Rodon, Jordi (Vall d'Hebron Institut d'Oncologia) ;
González-Cao, María (Quirón Dexeus University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ;
Berger, Michael F. (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona) ;
Reis-Filho, Jorge S. (Memorial Sloan Kettering Cancer Center) ;
Seoane Suárez, Joan (Universitat Autònoma de Barcelona)
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. [...]
2015 -  10.1038/ncomms9839
Nature communications, Vol. 6 (november 2015)
|
|
|
2.
|
|
12 p, 5.0 MB |
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
/
Vicario, Rocio (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Zacarias-Fluck, Mariano (Vall d'Hebron Institut d'Oncologia) ;
Zhang, Junjie (Vall d'Hebron Institut d'Oncologia) ;
Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ;
Navarro Jiménez, Alexandra (Hospital Universitari Vall d'Hebron) ;
Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Burgues, Octavio (Hospital Clínic Universitari (València)) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rubio, Isabel T. (Vall d'Hebron Institut d'Oncologia) ;
Marangoni, Elisabetta (Institut Curie) ;
Deeds, James (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Schlegel, Robert (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Mosher, Rebecca (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma (Suïssa)) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. [...]
2015 - 10.1371/journal.pone.0129876
PloS one, Vol. 10 (june 2015)
|
|
|
3.
|
|
13 p, 6.8 MB |
Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
/
Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ;
Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ;
Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Vidal, Maria (Vall d'Hebron Institut d'Oncologia) ;
Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Palmer, Héctor G. ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ;
Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports (Nature Publishing Group), Vol. 3 (december 2013)
|
|
|
4.
|
|
14 p, 3.0 MB |
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
/
Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Luque, Antonio (Vall d'Hebron Institut d'Oncologia) ;
Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ;
Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Dijcks, Fred A. (Preclinical R&D, The Netherlands) ;
Dokter, Wim H.A. (Preclinical R&D, The Netherlands) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. [...]
2020 - 10.3390/cancers12030670
Cancers, Vol. 12 (march 2020)
|
|
|
5.
|
|
16 p, 1.6 MB |
Integrating clinical, molecular, proteomic and histopathological data within the tissue context : tissunomics
/
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hümmer, Stefan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Peg, Vicente (Centro de Investigación Biomédica en Red de Cáncer) ;
Guiu, Xavier M (Hospital Universitari de Bellvitge) ;
de Torres, Inés (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Centro de Investigación Biomédica en Red de Cáncer) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona ;
VHIR Vall d'Hebron Institut de Recerca ;
Hospital Universitari Vall d'Hebron
Malignant tumours show a marked degree of morphological, molecular and proteomic heterogeneity. This variability is closely related to microenvironmental factors and the location of the tumour. The activation of genetic alterations is very tissue-dependent and only few tumours have distinct genetic alterations. [...]
2019 - 10.1111/his.13828
Histopathology, Vol. 75 (may 2019) , p. 4-19
|
|
|
6.
|
|
30 p, 7.5 MB |
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
/
De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ;
Sammut, S.J. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Ross, E.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Bashford-Rogers, R. (Department of Medicine. University of Cambridge) ;
Greenstein, E. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Markus, H. (Mayo Clinic Center for Individualized Medicine) ;
Morganella, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Teng, Y. (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ;
Maruvka, Y. (Massachusetts General Hospital) ;
Pereira, B. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Rueda, O.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Chin, S.F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Contente-Cuomo, T. (Mayo Clinic Center for Individualized Medicine) ;
Mayor, R. (Centro de Investigación Biomédica en Red de Cáncer) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Ali, H.R. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Cope, W. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Tiezzi, D. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Dariush, A. (Institute of Astronomy. University of Cambridge) ;
Dias Amarante, T. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Reshef, D. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Ciriaco, 0000-0002-1151-554X (Hospital Universitari Vall d'Hebron) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Vassiliou, G. (Wellcome Trust/MRC Cambridge Stem Cell Institute) ;
Getz, G. (Massachusetts General Hospital) ;
Nik-Zainal, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Murtaza, M. (Mayo Clinic Center for Individualized Medicine) ;
Friedman, N. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Markowetz, F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Caldas, C. (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ;
Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10
|
|
|
7.
|
|
14 p, 4.6 MB |
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
/
De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ;
Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ;
Piscuoglio, Salvatore (Institute of Pathology, University Hospital Basel) ;
Gonzalez-Cao, Maria (Grup Quirónsalud (Barcelona, Catalunya)) ;
Lim, Raymond S. (Memorial Sloan Kettering Cancer Center) ;
De Filippo, Maria R. (Memorial Sloan Kettering Cancer Center) ;
Fusco, Nicola (Memorial Sloan Kettering Cancer Center) ;
Schultheis, Anne M. (Memorial Sloan Kettering Cancer Center) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Macedo, Gabriel S. (Memorial Sloan Kettering Cancer Center) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Gomez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Teixidó, Cristina (Grup Quirónsalud (Barcelona, Catalunya)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tresserra Casas, Francesc (Grup Quirónsalud (Barcelona, Catalunya)) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ;
Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630
|
|
|
8.
|
|
12 p, 4.3 MB |
Beyond molecular tumor heterogeneity : protein synthesis takes control
/
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hümmer, Stefan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Pelletier, Jerry (Montreal, QC Canada) ;
Sonenberg, Nahum (Montreal, QC Canada) ;
Universitat Autònoma de Barcelona
One of the daunting challenges facing modern medicine lies in the understanding and treatment of tumor heterogeneity. Most tumors show intra-tumor heterogeneity at both genomic and proteomic levels, with marked impacts on the responses of therapeutic targets. [...]
2018 - 10.1038/s41388-018-0152-0
Oncogene, Vol. 37 (february 2018) , p. 2490-2501
|
|
|
9.
|
|
14 p, 6.9 MB |
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
/
Hergueta-Redondo, Marta (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Sarrio, David (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Molina-Crespo, Ángela (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Vicario, Rocío (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bernadó Morales, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez, Lidia (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Rojo-Sebastián, Alejandro (Pathology Department, MD Anderson Cancer Center, Madrid, Spain) ;
Serra-Musach, Jordi (Institut d'Investigació Biomèdica de Bellvitge) ;
Mota, Alba (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ;
Martínez-Ramírez, Ángel (Cytogenetics Department, MD Anderson Cancer Center, Madrid, Spain) ;
Castilla, Maria Ángeles (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
González-Martin, Antonio (Oncology Department, MD Anderson Cancer Center, Madrid, Spain) ;
Pernas, Sonia (Institut d'Investigació Biomèdica de Bellvitge) ;
Cano, Amparo (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Cortés, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Nuciforo, Paolo. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Palacios, José (Hospital Universitario Ramón y Cajal (Madrid)) ;
Pujana, Miguel Ángel (Institut d'Investigació Biomèdica de Bellvitge) ;
Arribas, Joaquín (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno-Bueno, Gema (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ;
Universitat Autònoma de Barcelona
Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. [...]
2016 - 10.18632/oncotarget.10787
Oncotarget, Vol. 7 (july 2016) , p. 56295-56308
|
|
|
10.
|
|
12 p, 1.1 MB |
peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas
/
Martínez Sáez, Elena (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Ortega Aznar, Arantxa (Hospital Universitari Vall d'Hebron) ;
Martínez Ricarte, Francisco (Hospital Universitari Vall d'Hebron) ;
Camacho, Jessica (Hospital Universitari Vall d'Hebron) ;
Hernández Losa, Javier (Hospital Universitari Vall d'Hebron) ;
Ferreres Piñas, Joan Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona.
Departament de Ciències Morfològiques
Malignant transformation in tumors is a complex process requiring accumulation of numerous oncogenic abnormalities. Brain tumors show considerable phenotypic and genetic heterogeneity. In a series comprising diffuse infiltrating astrocytomas () and reactive gliosis, we investigated the main factors associated with signaling pathways. [...]
2016 - 10.1002/cam4.817
Cancer Medicine, Vol. 5, issue 9 (Sep. 2016) , p. 2501-2512
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
